Regulus Therapeutics Statistics Share Statistics Regulus Therapeutics has 69.23M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 69.23M Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) 80.99% Shares Floating n/a Failed to Deliver (FTD) Shares 570 FTD / Avg. Volume 0.03%
Short Selling Information The latest short interest is 1.76M, so 2.54% of the outstanding
shares have been sold short.
Short Interest 1.76M Short % of Shares Out 2.54% Short % of Float 3.23% Short Ratio (days to cover) 1.35
Valuation Ratios The PE ratio is -1.92 and the forward
PE ratio is -7.7.
Regulus Therapeutics's PEG ratio is
0.04.
PE Ratio -1.92 Forward PE -7.7 PS Ratio 0 Forward PS 12.8 PB Ratio 1.17 P/FCF Ratio -2.12 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Regulus Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.98,
with a Debt / Equity ratio of 0.
Current Ratio 10.98 Quick Ratio 10.98 Debt / Equity 0 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage -316.71
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.36M Employee Count 34 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 1K Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 413.21% in the
last 52 weeks. The beta is 0.37, so Regulus Therapeutics's
price volatility has been higher than the market average.
Beta 0.37 52-Week Price Change 413.21% 50-Day Moving Average 6.9 200-Day Moving Average 2.83 Relative Strength Index (RSI) 66.62 Average Volume (20 Days) 2,158,092
Income Statement
Revenue n/a Gross Profit n/a Operating Income -50.04M Net Income -46.36M EBITDA -45.85M EBIT -46.2M Earnings Per Share (EPS) -0.82
Full Income Statement Balance Sheet The company has 38.53M in cash and 274K in
debt, giving a net cash position of 38.25M.
Cash & Cash Equivalents 38.53M Total Debt 274K Net Cash 38.25M Retained Earnings -559.57M Total Assets 74.83M Working Capital 67.3M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -41.67M
and capital expenditures -340K, giving a free cash flow of -42.01M.
Operating Cash Flow -41.67M Capital Expenditures -340K Free Cash Flow -42.01M FCF Per Share -0.75
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RGLS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for RGLS is $8,
which is -2% lower than the current price. The consensus rating is "Hold".
Price Target $8 Price Target Difference -2% Analyst Consensus Hold Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 29, 2022. It was a
backward
split with a ratio of 1:10.
Last Split Date Jun 29, 2022 Split Type backward Split Ratio 1:10
Scores Altman Z-Score 46.76 Piotroski F-Score 1
